Keap1-Nrf2-IN-21

• UNSPSC Description:

  Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC50=2.60 μM)[1].

• Target Antigen:

  Keap1-Nrf2

• Type:

  Reference compound

• Related Pathways:

  NF-κB

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/keap1-nrf2-in-21.html

• Smiles:

  O=C(C1=C2N(CC3=CN(CCCN4CCCCC4)N=N3)C(C(F)(F)F)=N1)C5=C(C2=O)C=CC=C5

• Molecular Weight:

  472.46

• References & Citations:

  [1]Yao Cheng, et al. "Design, synthesis and biological evaluation of glucose metabolism inhibitors as anticancer agents." Bioorganic Chemistry (2024): 107665.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported